Eli Lilly (LLY) is trying to make its obesity drug Zepbound more accessible, specifically for those individuals who may not have insurance. A 2.5 mg single-dose vial will now cost $399 per month while a four-week supply of the 5 mg dose will be $549. That's down from about $1,000 per month. The trade off is that these doses are sold via vials and will need a syringe and needle as opposed to the injector pens the pricier doses utilize.

Yahoo Finance healthcare reporter Anjalee Khemlani reports the details.

For more expert insight and the latest market action, click here to watch this full episode of Morning Brief.

This post was written by Stephanie Mikulich.